STROBE Statement—Checklist of items that should be included in reports of *cohort studies* For **Organophosphate Poisoning Induced Intermediate Syndrome Is a Spectrum Disorder**

	Item No	Recommendation
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract
		Page 3
		(b) Provide in the abstract an informative and balanced summary of what was
		done and what was found
		Pages 2-4
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
		Pages 5
Objectives	3	State specific objectives, including any prespecified hypotheses
		Page 5
Methods		
Study design	4	Present key elements of study design early in the paper
		Page 6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
		exposure, follow-up, and data collection
		Page 6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of
		participants. Describe methods of follow-up
		Page 6
		(b) For matched studies, give matching criteria and number of exposed and
		unexposed
		Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
		modifiers. Give diagnostic criteria, if applicable
		Not applicable
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there is
		more than one group
		Pages 6-7
Bias	9	Describe any efforts to address potential sources of bias
		Pages 6-7
Study size	10	Explain how the study size was arrived at
		The study was planned to conduct from January 26 and February 5 of 2020
		recruiting all eligible consenting patients admitted to two sections (one for
		severe patients, another for mild or moderate patients) of Chongqing Public
		Health Medical Center, the designated hospital for COVID-19 treatment in
		Chongqing central area.
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why
		Page 7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		4

		(d) If applicable, explain how loss to follow-up was addressed
		(<u>e</u>) Describe any sensitivity analyses
		All in Page 7
Results		
Participants	13*	 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included ir the study, completing follow-up, and analysed Page 9, table 1 and Supplementary Figure 1
		(b) Give reasons for non-participation at each stage
		Supplementary Figure 1
		(c) Consider use of a flow diagram
		Supplementary Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social)
	11	and information on exposures and potential confounders
		Page 9, table 1 and Supplementary Table 1-2
		(b) Indicate number of participants with missing data for each variable of interest
		in each Table, Supplementary Figure 1, and Page 11
		(c) Summarise follow-up time (eg, average and total amount)
		Page 6
Outcome data	15*	Report numbers of outcome events or summary measures over time
		Pages 9 and Supplementary Table 4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and
		their precision (eg, 95% confidence interval). Make clear which confounders were
		adjusted for and why they were included
		Page 12 and Table 6
		(b) Report category boundaries when continuous variables were categorized
		Yes, in each table.
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a
		meaningful time period Not applicable
Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions, and
		sensitivity analyses Not applicable
Discussion		
Key results	18	Summarise key results with reference to study objectives
		Page 13-14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or
		imprecision. Discuss both direction and magnitude of any potential bias
		Page 14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,
		multiplicity of analyses, results from similar studies, and other relevant evidence
		Pages 14
Generalisability	21	Discuss the generalisability (external validity) of the study results
		Page 14
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if
		applicable, for the original study on which the present article is based
		Yes, in Page 15

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.